• OPEN AN ACCOUNT
Indian Indices
Nifty
24,620.20 77.70
(0.32%)
Sensex
80,998.25 260.74
( 0.32%)
Bank Nifty
55,676.85 76.90
( 0.14%)
Nifty IT
36,938.10 123.20
( 0.33%)
Global Indices
Nasdaq
42,543.92 217.44
(0.51%)
Dow Jones
5,991.81 34.87
(0.59%)
Hang Seng
37,806.65 359.84
(0.96%)
Nikkei 225
8,787.02 12.76
(0.15%)
Forex
USD-INR
85.40 -0.14
(-0.17%)
EUR-INR
97.46 0.39
(0.40%)
GBP-INR
115.51 0.44
(0.39%)
JPY-INR
0.60 0.00
(0.58%)

EQUITY - MARKET SCREENER

Divis Laboratories Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value()
532488
INE361B01024
561.0868795
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
DIVISLAB
78.48
173357.62
EPS(TTM)
Face Value()
Div & Yield %
83.21
2
0.46
 

divis laboratories ltd
Divis Lab inks long-term global pharma deal
May 24,2025
As part of the agreement, Divis will manufacture and supply advanced pharmaceutical intermediates to the global partner. The company has stated that the contract is expected to contribute meaningfully to its revenue over the long term.

To support the execution of this deal, Divis plans to invest between Rs 650 crore and Rs 750 crore to expand its manufacturing capacity. This investment will be funded through capacity reservation advances that will be paid in phases by the customer.

Divis Laboratories believes the partnership will not only ensure a reliable supply chain for the customer but also allow the company to strengthen its foothold in the custom synthesis space.

The company clarified that the deal does not involve any share exchange or related party transactions. There is no involvement of the promoter group or affiliated companies in the agreement.

Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit jumped 23.04% to Rs 662 crore while revenue from operations grew by 12.24% to Rs 2,585 crore in Q4 March 2025 over Q4 March 2024.